Epsilon Healthcare (ASX: EPN) Climbs 14.29%: Can Record Receipts Keep the Growth Story Moving?

Aditi Sarkar

01 September 2026 01:56 PM AEST

Epsilon Healthcare (ASX: EPN) Climbs 14.29%: Can Record Receipts Keep the Growth Story Moving?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Epsilon Healthcare reported record quarterly receipts of AUD 3.66mn for the June 2026 quarter.
Quarterly receipts increased 72% year on year and 17% from the previous quarterly high.
Group Revenue reached AUD 4.7mn for the quarter.
EPN shares rose 14.29% to AUD 0.024 at the time of writing on 1 September 2026.

Epsilon Healthcare (ASX: EPN) shares rose 14.29% to AUD 0.024 at the time of writing on 1 September 2026. Epsilon Healthcare Limited (ASX: EPN) reported a significant operating milestone in its 30 July 2026 quarterly activities report. The company recorded quarterly receipts of AUD 3.66mn for the June 2026 quarter, its highest quarterly level to date and a 17% increase on the previous quarterly high. The release gives the latest detailed view of operating receipts and activity across the group.

Revenue Tracks the Higher Activity

Group revenue reached AUD 4.7mn for the quarter, while year-to-date revenue averaged AUD 1.33mn per month, equivalent to an annualised pace of about AUD 16mn. The figures provide the financial backdrop to the company’s latest operating update and show the scale of activity recorded during the quarter. The company’s cash-flow disclosure also reported net cash from Operating Activities of AUD 1.068mn for the quarter.

Epsilon Pharma Drives Manufacturing Growth

Epsilon Pharma, the company’s onshore contract development and manufacturing organisation, recorded 122% year-on-year growth in the June quarter. The result was linked in the company announcement to expanding manufacturing activities, placing the CDMO Business at the centre of the latest operational update. The manufacturing performance is therefore a key component of the quarterly results released by the company.

EPN Share Price at the Time of Writing

At the time of writing on 1 September 2026, EPN shares rose 14.29% to AUD 0.024. The company’s latest operating story remains centred on receipts, revenue and manufacturing activity. Subsequent quarterly reporting will provide the next operating comparison.

FAQs

Q: What were Epsilon Healthcare’s June-quarter receipts?

A: Quarterly receipts were AUD 3.66mn, the highest in the company’s history.

Q: How much did receipts grow year on year?

A: June-quarter receipts increased 72% year on year.

Q: What happened at Epsilon Pharma?

A: Epsilon Pharma recorded 122% year-on-year growth in the June quarter as manufacturing activity expanded.

Q: What was the EPN share price at the time of writing?

A: EPN traded at AUD 0.024 at the time of writing on 1 September 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.